In the preparation of this PD-L1 monoclonal antibody, mouses were selected as the host animal. A Recombinant Human Programmed cell death 1 ligand 1 protein was injected into the mouse to immunize it. Next, the spleen cells were removed from the mouse and fuse B cells in the spleen cells with myeloma cells, using the hybridoma technology. And the hybridoma was obtained in the process, which was featured with the properties of growing in culture and producing PD-L1 monoclonal antibody. This PD-L1 antibody has been purified by Protein G and validated in ELISA, WB, IHC, IF, FC.
PD-L1 (Programmed death-ligand 1), also known as CD274 or B7 homolog 1 (B7-H1), is encoded by the CD274 gene. PD-L1 is a class I transmembrane protein with a size of 40 kDa, with a total length of 290 amino acids, including an IgV-like region, an IgC-like region, a transmembrane hydrophobic region and an intracellular region. PD-L1 is the ligand of PD-1, which is commonly expressed in antigen-presenting cells, macrophages, activated T cells, B cells, monocytes, endothelial cells, etc.
Immune checkpoints include CTLA4-CD80, PD-1-PD-L1/PD-L2, GAL9-TIM3, etc., among which PD-1-PD-L1 has become a research hotspot in tumor immunity in recent years. PD-1 is an important negative regulatory molecule for immune cell activation. By combining with PD-L1, it produces a variety of biological effects such as inhibiting the proliferation and activation of lymphocytes, inhibiting the release of cytokines, etc., thereby exerting immunosuppressive effects. Through the high expression of PD-1 and PD-L1, tumor cells go through the three processes of clearance, balance, and escape of the immune microenvironment, and eventually may escape the body's immune system and form tumors.